Biohaven reports fourth quarter and full year 2023 financial results and recent business developments

Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessive-compulsive disorder (ocd), migraine, pain, alzheimer's disease, parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. also advancing potential novel treatments for rare autoimmune and inflammatory diseases, including myasthenia gravis, cardiomyopathy, spinal muscular atrophy (sma) and iga nephropathy.
BHVN Ratings Summary
BHVN Quant Ranking